natgillin/translations-raw huggingface dataset:
A pharmaceutical product comprising (A) a first component which comprises, as an active agent, Compound I or a pharmaceutically-acceptable salt thereof; (B) a second component which comprises, as an active agent, cetuximab; and (C) a third component which comprises, as an active agent, irinotecan or a pharmaceutically-acceptable salt thereof; as a combined preparation for simultaneous or sequential use in the treatment of cancer comprising b-Raf having a V600 mutation, wherein 
Farmaceutski proizvod, naznačen time, da obuhvaća (A) prvi sastojak koji, kao djelatnu tvar, sadrži Spoj I ili njegovu farmaceutski prihvatljivu sol; (B) drugi sastojak koji, kao djelatnu tvar, sadrži cetuksimab; i (C) treći sastojak koji, kao djelatnu tvar, sadrži irinotekan ili njegovu farmaceutski prihvatljivu sol; kao kombinirani pripravak za istovremenu ili uzastopnu uporabu u liječenju raka koji obuhvaća b-Raf s V600-mutacijom, pri čemu
is administered in an amount of from about 50 mg/m2/week to about 700 mg/m2/week, from about 100 mg/m2/week to about 600 mg/m2/week, or from about 200 mg/m2/week to about 500 mg/m2/week; and 
se primjenjuje u količini od oko 50 mg/m2/tjedan do oko 700 mg/m2/tjedan, od oko 100 mg/m2/tjedan do oko 600 mg/m2/tjedan, ili od oko 200 mg/m2/tjedan do oko 500 mg/m2/tjedan; te
is administered in an amount of from about 1 to about 250 mg/m2/week, about 50 to about 200 mg/m2/week, or about 125 mg/m2/week. 
se primjenjuje u količini od oko 1 mg/m2/tjedan do oko 250 mg/m2/tjedan, oko 50 mg/m2/tjedan do oko 200 mg/m2/tjedan, ili oko 125 mg/m2/tjedan.
The ranolazine for use according to claim 1, wherein the dronedarone or the salt thereof and the ranolazine are administered separately or together as a combined dosage unit, wherein the combined dosage unit is preferably a tablet. 
Ranolazin za primjenu prema patentnom zahtjevu 1, gdje su dronedaron ili njegova sol i ranolazin davani odvojeno ili zajedno kao kombinirana dozna jedinica, gdje je poželjno da je kombinirana dozirana jedinica, tableta.
The ranolazine for use according to claim 6, wherein the amount of the dronedarone or the salt thereof administered is from about 50 mg to about 200 mg daily. 
Ranolazin za primjenu prema patentnom zahtjevu 6, gdje je količina dronedarona ili njegove soli koja je davana od oko 50 mg do oko 200 mg dnevno.
A pharmaceutical formulation comprising ranolazine and dronedarone or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutska formulacija koja sadrži ranolazin i dronedaron ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljivi nosač.
The pharmaceutical formulation of claim 9, formulated for intravenous administration or oral administration. 
Farmaceutska formulacija patentnog zahtjeva 9, koja je formulirana za intravensku primjenu ili oralno uzimanje.
The pharmaceutical formulation of claim 9, wherein the formulation is in a tablet form or a capsule form. 
Farmaceutska formulacija patentnog zahtjeva 9, gdje je formulacija u obliku tablete ili kapsule.
The formulation of claim 11, wherein the tablet or capsule comprises from about 25 mg to about 600 mg, preferably from about 50 mg to about 200 mg of the dronedarone or the salt thereof. 
Formulacija patentnog zahtjeva 11, gdje tableta ili kapsula sadrži od oko 25 mg do oko 600 mg, poželjno od oko 50 mg do oko 200 mg dronedarona ili njegove soli.
The formulation of claim 11 or 12, wherein the tablet or capsule comprises from about 50 mg to about 1000 mg, preferably from about 100 mg to about 750 mg of the ranolazine. 
Formulacija patentnog zahtjeva 11 ili 12, gdje tableta ili kapsula sadrži od oko 50 mg do oko 1000 mg, poželjno od oko 100 mg do oko 750 mg ranolazina.
The formulation of any one of claims 9-15, wherein the dronedarone or salt thereof is formulated for immediate release or sustained release. 
Formulacija prema bilo kojem od patentnih zahtjeva 9-15, gdje je dronedaron ili njegova sol formuliran za momentalno oslobađanje ili produženo oslobađanje.
precipitating a cryo-poor plasma fraction, in a first precipitation step, with between about 6% and about 10% alcohol at a pH of between about 6.7 and about 7.3 to obtain a supernatant enriched in IgG, 
taloženje krio-siromašne frakcije plazme, u prvoj fazi taloženja, s oko 6% do 10% alkohola na pH-vrijednosti od oko 6,7 do oko 7,3, za dobivanje sloja koji ispliva na površinu obogaćenog s IgG,
re-suspending the first precipitate formed in step (b) to form a suspension, 
re-suspendiranje prvog taloga stvorenog u koraku (b) za tvorbu suspenzije,
treating the suspension formed in step (c) with a detergent, 
obrada suspenzije stvorene u koraku (c) s deterdžentom,
re-suspending the second precipitate formed in step (e) to form a suspension, 
re-suspendiranje drugog taloga stvorenog u koraku (e), za tvorbu suspenzije,
treating the suspension formed in step (f) with a solvent and/or detergent, and 
obrada suspenzije stvorene u koraku (f) s otapalom i/ili deterdžentom, i
between about 24% and about 26%, or 
između oko 24% i oko 26%,
at or about 6.9. 
na ili oko 6,9.
The method of any one of claims 1 to 3, wherein in step (b), after completion of the alcohol addition, the pH of the solution is immediately adjusted to 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time, da u koraku (b), nakon dovršetka dodavanja alkohola, pH-vrijednost otopine se odmah namjesti:
between about 6.8 and about 7.0, or to 
između oko 6,8 i oko 7,0, ili
at about 6.9 continuously during the precipitation incubation period of step (b). 
na oko 6,9 stalno za vrijeme inkubacijskog perioda taloženja u koraku (b).
The method of claim 7, wherein the extraction buffer contains 5 mM monobasic sodium phosphate, 5 mM acetate, and 0.051% to 0.06% glacial acetic acid (v/v). 
Postupak prema zahtjevu 7, naznačen time, da puferski ekstrakt sadrži 5 mM monobazičnog natrijevog fosfata, 5 mM acetata i 0,051% do 0,06% glacijalne octene kiseline (v/v).
An instant coffee with coffee grounds and foam characterized by 65% to 97.5% on dry matter of roasted and ground coffee beans and 2.0% to 2.5% on dry matter of flavoring substance obtained by a production method comprising the steps of 
Instant kava sa talogom i pjenom okarakterizirana sa 65% do 97.5% suhe tvari pečenih i mljevenih zrna kave i 2.0% do 2.5% suhe tvari supstance za poboljšanje ukusa dobijena proizvodnom metodom koja obuhvaća korake
mixing the roasted coffee bean with the other materials 
miješanje pečenog zrna kave sa drugim tvarima
drying the agglomerated mixture and 
sušenje sakupljene mješavine i
cooling the dried mixture. 
hlađenje osušene mješavine.
A production method for obtaining an instant coffee according to Claim 1, comprising the step of packaging the cooled powder in a nitrogen gas medium. 
Proizvodna metoda za dobijanje instant kave prema zahtjevu 1, koja sadrži korak pakiranja ohlađenog praška u mediju plinovitog dušika.
An instant coffee according to Claims 1 or 2, characterized by a production method comprising a packaging step for single use packages realized under nitrogen gas. 
Instant kava prema zahtjevima 1 ili 2, okarakterizirana proizvodnom metodom koja sadrži korak pakiranja za pakete za jednokratnu uporabu koji se izvodi u prisustvu plinovitog dušika.
An instant coffee according to Claims 1, 2 or 3, characterized by a production method comprising a grinding step which enables the particle size of the mixture to be processed into 10 to 90 microns. 
Instant kava prema zahtjevima 1, 2 ili 3, okarakterizirana proizvodnom metodom koja sadrži korak mljevenja koji omogućava da veličina čestica mješavine bude obrađena do veličine 10 do 90 mikrona.
An instant coffee according to any of the preceding claims which is soluble in water in an amount of 25% to 50% on dry matter when mixed with hot water. 
Instant kava prema bilo kojem od prethodnih zahtjeva koja je topiva u vodi u količini od 25% do 50% suhe tvari kada je pomješana sa vrućom vodom.
An instant coffee according to any of the preceding claims, characterized by a flavoring substance comprising natural extracts, volatile oils, nature-identical flavoring substances used as flavoring agents, maltodextrin used as a carrier, thickener agents enabling binding together, milk powder, stabilizer which ensures stability of the mixture, emulsifying salt and anticaking agent. 
Instant kava prema bilo kojem od prethodnih zahtjeva, okarakterizirana supstancom za poboljšanje okusa koja obuhvaća prirodne ekstrakte, isparljiva ulja, supstance za poboljšanje okusa koje su identične prirodnim koje su korištene kao poboljšivači okusa, maltodekstrinom koji je korišten kao nositelj, zgušnjivačima koji omogućavaju vezivanje, mlijekom u prahu, stabilizatorom koji osigurava stabilnost mješavine, emulgirajućom soli i agensom koji sprječava grupiranje.
An instant coffee according to Claim 7, characterized by an emulsifying salt which is provided in the flavoring substance and which is disodium phosphate. 
Instant kava prema zahtjevu 7, okarakterizirana emulgirajućom soli koja je prisutna u supstanci za poboljšanje okusa i koja je dinatrij fosfat.
An instant coffee according to Claim 7 or 8, characterized by an anticaking agent which is provided in the flavoring substance and which is silicon dioxide. 
Instant kava prema zahtjevu 7 ili 8, okarakterizirana agensom koji sprječava grupiranje koji je prisutan u supstanci za poboljšanje okusa i koji je silikon dioksid.
An instant coffee according to any of Claims 7 to 9, characterized by a flavoring substance which has Turkish delight flavor. 
Instant kava prema bilo kojem od zahtjeva 7 do 9, okarakterizirana supstancom za poboljšanje okusa koja ima okus ratluka.
An instant coffee according to any of Claims 7 to 9, characterized by a flavoring substance which has mastic flavor. 
Instant kava prema bilo kojem od zahtjeva 7 do 9, okarakterizirana supstancom za poboljšanje okusa koja ima okus mastike.
An instant coffee according to any of Claims 7 to 9, characterized by a flavoring substance which has coconut flavor. 
Instant kava prema bilo kojem od zahtjeva 7 do 9, okarakterizirana supstancom za poboljšanje okusa koja ima okus kokosa.
An instant coffee according to any of Claims 7 to 9, characterized by a flavoring substance which has almond flavor. 
Instant kava prema bilo kojem od zahtjeva 7 do 9, okarakterizirana supstancom za poboljšanje okusa koja ima okus badema.
An instant coffee according to any of Claims 7 to 9, characterized by a flavoring substance which has hazelnut flavor. 
Instant kava prema bilo kojem od zahtjeva 7 do 9, okarakterizirana supstancom za poboljšanje okusa koja ima okus lješnjaka.
An instant coffee according to any of Claims 7 to 9, characterized by a flavoring substance which has cardamom flavor. 
Instant kava prema bilo kojem od zahtjeva 7 do 9, okarakterizirana supstancom za poboljšanje okusa koja ima okus kardamona.
An instant coffee according to any of Claims 7 to 9, characterized by a flavoring substance which has chocolate flavor. 
Instant kava prema bilo kojem od zahtjeva 7 do 9, okarakterizirana supstancom za poboljšanje okusa koja ima okus čokolade.
An instant coffee according to any of Claims 7 to 9, characterized by a flavoring substance which has mint flavor. 
Instant kava prema bilo kojem od zahtjeva 7 do 9, okarakterizirana supstancom za poboljšanje okusa koja ima okus mente.
An instant coffee according to any of Claims 7 to 9, characterized by a flavoring substance which has fruit flavors. 
Instant kava prema bilo kojem od zahtjeva 7 do 9, okarakterizirana supstancom za poboljšanje okusa koja ima okus voća.
Pharmaceutical composition comprising GSNO as active ingredient together with usual additives and with one or more pharmaceutically acceptable polymers(s) selected from the group of polysaccharides, PVA, PVP, PEG, alginic acid and its salts, where the pH value of the composition is about 8-9. 
Farmaceutski sastav obuhvaća GSNO kao aktivni sastojak zajedno s uobičajenim aditivima i jedan ili više farmaceutski prihvatljivih polimera odabranih iz grupe polisaharida, PVA, PVP, PEG, alginske kiseline i njenih soli, gdje je pH vrijednost sastava približno 8-9.
Pharmaceutical composition according to claim 1 characterized in that the composition is an aqueous gel and contains PVA and PEG polymers as pharmaceutically acceptable polymer, optionally together with a polysaccharide. 
Farmaceutski sastav u skladu s patentnim zahtjevom 1 karakteriziran na način da je sastav vodeni gel i sadrži PVA i PEG polimere kao farmaceutski prihvatljive polimere, opcionalno zajedno s polisaharidom.
Pharmaceutical composition according to claim 1 or 2 characterized in that it is in solid form prepared by drying, preferably by lyophilizing of a composition according to claim 1 or 2. 
Farmaceutski sastav u skladu s patentnim zahtjevom 1 ili 2 karakteriziran na način da je čvrsti oblik pripravljen sušenjem, poželjno liofiliziranjem sastava iz patentnog zahtjeva 1 ili 2.
223Ra as claimed in any of claims 2 to 5 wherein the method purifies sufficient 223Ra for more than 10 typical doses. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 5 pri čemu metoda pročišćava dovoljno 223Ra za više od 10 uobičajenih doza.
223Ra as claimed in any of claims 2 to 6 wherein a 227Ac radioactivity of at least 500 MBq is employed in step i) 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 6 pri čemu je radioaktivnost 227Ac od najmanje 500 MBq primijenjena u koraku i).
223Ra as claimed in any of claims 2 to 7 wherein the strong base anion exchange resin is a polystyrene/divinyl benzene copolymer based resin, preferably containing1- 95 % DVB and/or is an R-N+Me3 type (type I) resin or an R-N-Me2CH2CH2OH (Type II) resin. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 7 pri čemu je jako kisela kationska izmjenjivačka smola temeljena na smoli kopolimera polistiren/divinil benzena, poželjno sadržava 1 – 95% DVB i/ili je smola R-N+Me3 tipa (tip I) ili smola R-N+Me2CH2CH2OH (tip II).
223Ra as claimed in any of claims 2 to 8 wherein the first mineral acid is an acid selected from H2SO4 and HNO3, preferably HNO3 and/or is used at a concentration of 0.01 to 5 M. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 8 pri čemu je prva mineralna kiselina kiselina odabrana između H2SO4 i HNO3, poželjno HNO3 i/ili je upotrijebljena u koncentraciji od 0,01 do 5 M.
223Ra as claimed in any of claims 2 to 10 wherein the alcoholic aqueous solution may comprises 20 to 99% methanol. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 10 pri čemu alkoholna vodena otopina može sadržavati 20 do 99% metanola.
223Ra as claimed in of claims 2 to 11 wherein the first eluted solution has a contamination level of no more than 100 Bq 227Ac per 1MBq 223Ra. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 11 pri čemu prva eluirana otopina ima razinu onečišćenja ne višu od 100 Bq 227Ac po 1 MBq 223Ra.
223Ra as claimed in any of claims 2 to 12 wherein the steps of loading the generator mixture onto the base anion exchange resin and eluting the first eluted 223Ra solution provide a separation ratio of 223Ra to 227Ac of at least 10,000:1. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 12 pri čemu koraci nanošenja generacijske smjese na bazičnu anionsku izmjenjivačku smolu i eluiranje prve eluirane otopine 223Ra omogućavaju omjer razdvajanja 223Ra prema 227Ac od najmanje 10000:1.
223Ra as claimed in any of claims 2 to 13 wherein the strong acid cation exchange resin is a polystyrene/divinyl benzene copolymer based resin, preferably containing 1- 95 % DVB and/or is of SO3H type. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 12 pri čemu jako kisela kationska izmjenjivačka smola temeljena na smoli kopolimera polistiren/divinil benzena, poželjno sadržava 1 – 95% DVB i/ili je SO3H tipa.
223Ra as claimed in any of claims 2 to 14 wherein the second mineral acid is an acid selected from H2SO4, HNO3 and HCl, preferably HNO3 and/or is used at a concentration of 0.5 to 5 M. 
Metoda iz bilo kojeg od patentnih zahtjeva 1 do 13 pri čemu je druga mineralna kiselina kiselina odabrana između H2SO4, HNO3 i HCl, poželjno HNO3 i/ili je upotrijebljena u koncentraciji od 0,5 do 5 M.
A nasal spray device as claimed in claim 1, wherein a maximum transverse dimension of the transfer channel (13) is greater than a diameter of the discharge orifice (19). 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu je maksimalna transverzalna dimenzija prijenosnog kanala (13) veća od promjera ispusnog otvora (19).
A nasal spray device as claimed in claim 1, wherein a maximum transverse dimension of the transfer channel (13) is from 1.0 to 3.0 mm. 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu je maksimalna transverzalna dimenzija prijenosnog kanala (13) od 1.0 do 3.0 mm.
A nasal spray device as claimed in claim 1, wherein the transfer channel (13) has a circular cross-section. 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu prijenosni kanal (13) ima kružni poprečni presjek.
A nasal spray device as claimed in claim 1, wherein the transfer channel (13) has a transverse dimension which tapers down towards an end of the discharge orifice (19). 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu prijenosni kanal (13) ima transverzalnu dimenziju koja se sužava prema kraju ispusnog otvora (19).
A nasal spray device as claimed in claim 1, wherein the co-solvent is present at 0.5 to 20% w/w, based on a total weight of the pharmaceutical formulation. 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu je suotapalo prisutno u količini od 0.5 do 20% w/w, temeljem ukupne težine farmaceutske formulacije.
A nasal spray device as claimed in claim 1, wherein the pharmaceutical formulation is a solution formulation. 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu je farmaceutska formulacija formulacija otopine.
A nasal spray device as claimed in claim 1, wherein the pharmaceutical formulation is a suspension formulation. 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu je farmaceutska formulacija suspenzijska formulacija.
A nasal spray device as claimed in claim 1 or 2, wherein a maximum transverse dimension of the transfer channel (13) is greater than a diameter of the discharge orifice (19). 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu je maksimalna transverzalna dimenzija prijenosnog kanala (13) veća od promjera ispusnog otvora (19).
A nasal spray device as claimed in any preceding claim, wherein the transfer channel (13) has a circular cross-section. 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu prijenosni kanal (13) ima kružni poprečni presjek.
A nasal spray device as claimed in any preceding claim, wherein the transfer channel (13) has a transverse dimension which tapers down towards an end of the discharge orifice (19). 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu prijenosni kanal (13) ima transverzalnu dimenziju koja se sužava prema kraju ispusnog otvora (19).
A nasal spray device as claimed in any preceding claim, wherein the co-solvent is present at 0.5 to 20% w/w, based on a total weight of the pharmaceutical formulation. 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu je suotapalo prisutno u količini od 0.5 do 20% w/w, temeljem ukupne težine farmaceutske formulacije.
Apparatus according to any one of claims 2 to 9 wherein the tubular structure (21) undergoes compression as a result of tension which is exerted on the tubular structure (21) by virtue of axial tension on the belt portion (15) and also tension arising from the loading exerted by material contained within the tubular structure (21). 
Uređaj prema bilo kojem od prethodnih zahtjeva, naznačen time da je cjevasta struktura (21) podvrgnuta pritisku koji je rezultat naprezanja koje je posredstvom aksijalnog naprezanja na dijelu trake i također naprezanja koje proizlazi iz opterećenja koje vrši materijal koji se nalazi unutar cjevaste strukture (21) nametnuto na cjevastu strukturu (21).
coating a nanoparticle with an SSN, wherein the nanoparticle is a dendrimeric nanomatrix or a nanoparticle that is coated with a cell-penetrating peptide; 
oblaganje nanočestice sa SSN, naznačeno time da je nanočestica dendrimerna nanomatrica ili nanočestica koja je obložena sa u stanicu penetrirajućim peptidom;
placing the cell having a cell wall and the coated nanoparticle in contact with each other; and allowing uptake of the nanoparticle and the SSN into the plant cell comprising a cell wall. 
stavljanje stanice koja ima stanični zid i obložene nanočestice u međusobni kontakt; i dopuštanje unosa nanočestice i SSN u stanicu biljke koja sadrži stanični zid.
A method according to claim 1, further comprising first providing the plant cell having a cell wall. 
Postupak prema zahtjevu 1, koji nadalje obuhvaća prvo pribavljanje biljne stanice koja ima stanični zid.
The method according to claim 2, further comprising allowing uptake of the nanoparticle into a compartment of the plant cell comprising a cell wall. 
Postupak prema zahtjevu 2, koji nadalje obuhvaća dopuštanje unosa nanočestice u odjeljak biljne stanice koji sadrži stanični zid.
The method according to claim 5, wherein the compartment is selected from the group consisting of cytosol, nucleus, tonoplasts, plastid, etioplast, chromoplast leucoplast, elaioplast, proteinoplast, amyloplast, chloroplast, and the lumen of the double membrane. 
Postupak prema zahtjevu 5, naznačen time da je odjeljak odabran iz grupe koja se sastoji od citosola, jezgre, tonoplasta, plastida, etioplasta, kromoplast leukoplasta, elaioplasta, proteinoplasta, amiloplasta, kloroplasa i lumena dvostruke membrane.
The method of any one of the previous claims, wherein the plant cell is from a tissue selected from the group consisting of embryo, meristematic, callus, pollen, leaves, anthers, roots, root tips, flowers, seeds, pods and stems. 
Postupak prema bilo kojem od predhodnih zahtjeva, naznačen time da je biljna stanica iz tkiva izabranih iz grupe koja se sastoji od embrija, meristematic, kalusa, peluda, lišća, prašnika, korijena, vršaka korijena, cvijeta, sjemenja, mahuna i stabljika.
The method according to any one of the previous claims, wherein the nanoparticle is selected from the group consisting of gold nanoparticles, gold coated nanoparticles, porous nanoparticles, mesoporous nanoparticles, silica nanoparticles, polymer nanoparticles, tungsten nanoparticles, gelatin nanoparticles, nanoshells, nanocores, nanospheres, nanorods, magnetic nanoparticles, semiconductor nanoparticles, quantum dots, nanomatrices, dendrimeric nanomatrices and combinations thereof. 
Postupak prema bilo kojem od predhodnih zahtjeva, naznačen time da su nanočestice izabrane iz grupe koja se sastoji od zlatnih nanočestice, zlatom obloženih nanočestica, poroznih nanočestica, mezoporoznih nanočestica, silikonskih nanočestica, polimernih nanočestica, volframovih nanočestica, želatin nanočestica, nano školjki, nano jezgri, nano sfera, nano šipki, magnetskih nanočestica, poluvodičkih nanočestica, kvantnih točkica, nanomatrica, dendrimernih nanomatrica i njihovih kombinacija.
The method of claim 2, wherein the SSN is a zinc finger nuclease comprised of a zinc finger protein with a sequence-independent nuclease domain preferably derived from the Type IIS restriction endonuclease Fokl. 
Postupak prema zahtjevu 2, naznačen time da je SSN cink finger nukleaza koja se sastoji od cink finger proteina sa sekvenca-neovisnom nukleaznom domenom poželjno izvedenom iz restrikcijske endonukleaze Fokl tipa IIS.
The method according to claim 14, further comprising regenerating a plant from the regenerable cells. 
Postupak prema zahtjevu 14, koji nadalje obuhvaća regeneriranje biljke iz regenerabilnih stanica.
A composition comprising a nanoparticle coated with an SSN, wherein the nanoparticle is a dendrimeric nanomatrix or a nanoparticle that is coated with a cell-penetrating peptide. 
Kompozicija koja obuhvaća nanočesticu obloženu sa SSN, naznačena time da je nanočestica dendrimerna nanomatrica ili nanočestica koja je obložena sa u stanicu penetrirajućim peptidom.